Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

of Actavis Group. 

Actavis Specialty Brands R&D investment in the fourth quarter increased $23.8 million due to higher in-licensing costs and increased costs related to our biosimilar product development.  Actavis Specialty Brands selling and marketing expenses decreased by $1.2 million to $45.3 million in the fourth quarter, primarily due to lower promotional spending in the U.S., partially offset by higher commercial spending in Canada.

For the full year 2012, Actavis Specialty Brands segment net revenue increased 9 percent to $482.4 million, due to increased sales of Generess Fe® which was launched in the second quarter of 2011 and sales growth for key promoted products including  Rapaflo® and Crinone® and the addition of  Kadian®.

Actavis Specialty Brands segment adjusted gross margin for the full year 2012 was 76.1 percent, compared to 78.7 percent in 2011 as a result of product mix. Anda Distribution Segment InformationThree Months EndedTwelve Months EndedDecember 31, December 31,(Unaudited; $ in millions)2012201120122011Net revenue

$
203.9$
251.4$
986.4$
776.2Operating expenses:Cost of sales

168.1214.6846.6652.7Selling and marketing

21.320.889.877.2Segment contribution

$
4.5$
.0$
50.0$
46.3Segment margin

7.1%6.4%5.1%6.0%Gross profit

$
35.8$
36.8$
39.8$
23.5Gross margin

17.6%14.6%14.2%15.9%Anda Distribution segment net revenue for the fourth quarter 2012 decreased 19 percent to $203.9 million compared to $251.4 million in the fourth quarter 2011 due to lower chain sales offset by new product launches. Anda Distribution segment revenue consists only of sales of third-party products and excludes sales of Actavis' brand and generic products.

Anda Distribution segment gross margin increased 300 basis points to 17.6 percent in the fourth quarter 2012, prim
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... to whole range ... of Phase II, III and IV Clinical Trials, ... in off-the-shelf and custom supply chain software for the,biopharmaceutical, ... its tcVisualize(TM) 3.0 clinical trial supply simulator. The,latest generation ...
... the,European Society of Cardiology Congress 2007 (ESC Congress 2007) ... clinical benefits compared to a bare metal stent in ... no differences in safety. At five-year follow-up, the ... to be significantly less likely than the patients in ...
Cached Medicine Technology:Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country singer ... diagnosed with the Alzheimer’s, inspired Seniors Guide writers to review ... The movie, out on October 14, 2014, shows a glimpse ... the disease – which inspires a final tour from the ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... in five patients operated on for broken bones or other ... new study finds. Less-educated patients and patients who ... to be "doctor shoppers," said study lead author Dr. Brent ... he said, the study suggests that doctors aren,t talking to ...
(Date:8/30/2014)... medication commonly used to treat gout, before and ... potential complications from this type of surgery, but ... effects, according to a study published by ... online to coincide with its presentation at the ... after cardiac surgery include postpericardiotomy syndrome (the occurrence ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
Breaking Medicine News(10 mins):Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... is a breach of trust if the court orders to release ... doctor and a patient.// The hospital said that it would do ... who had an abortion at 32 weeks' pregnancy. She plans to ... of Appeal ordered that the woman's files be released to the ...
... OnlySuccess Learning Technologies, a training company based in Chennai, ... children in Dubai and Sharjah. // ... adults with flagship programmes 'Born to Win' and 'Superbkids/Superbteens', ... performances. ,The company currently enjoys a ...
... (IIT) Delhi has developed a high-tech stick to make walking ... // ,Called "smart cane", the stick will help ... inside a room without knocking into things and take a ... technology has been developed by students of the computer science ...
... published on bmj.com in February, that found that the number ... concern among doctors. // They stated that there has been ... that this was true even among low risk women aged ... ,The study also showed that this was probably ...
... Hypnotherapy can be used to relieve pain such as chest ... study researchers randomly divided 28 patients with the condition into ... of hypnotherapy over 17 weeks while the other group ... , ,According to the BMJ, the researchers found that ...
... Association of Clinical Endocrinologists (AACE) Fifteenth Annual Meeting and ... Chicago between April 26-30 will discuss important benefits //of ... deficiency. ,Vitamin D has been ... to heart disease has been attributed to it. Recent ...
Cached Medicine News:Health News:Bad Publicity for the Hospital With Respect To Dwarfism Abortion Case 2Health News:Hi-tech Walking Stick Developed For Visually Impaired 2Health News:Concern Over The Rise In Preterm Deliveries 2
... These award-winning surgical loupes from SheerVision ... users - high resolution optics combined with ... "xx" Ultra-Light loupes weight as little as ... titanium frame, and are available in either ...
... SheerVision manufactures its signature line of ... Sport Frame. These next generation loupes ... ultra-lightweight design, and are multi-coated lens for ... the SV Sport frame offers a stylish, ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
... now the first manufacturer to offer ... the wearer. These next generation loupes ... an ultra-lightweight design, and are multi-coated ... resistance. With SheerVision's proprietary SureFit system ...
Medicine Products: